Abstract
The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3%), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7%), 35 (97.2%), and 0 (0%), respectively. MMR proteins and ARID1A were retained in 100%; PTEN was lost in 4 (11.1%). P53 was aberrant in 10 (27.8%); none overexpressed p16. HER2 was positive in 6/35 (17.1%). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/−, CDX2+/−, PAX8−, ER−, PgR−, and SATB2−. HER2 positivity suggests a possible target for therapy in advanced disease.
Original language | English (US) |
---|---|
Pages (from-to) | 306-317 |
Number of pages | 12 |
Journal | International Journal of Surgical Pathology |
Volume | 26 |
Issue number | 4 |
DOIs | |
State | Published - Jun 1 2018 |
Externally published | Yes |
Fingerprint
Keywords
- HER2
- HNF1b
- PAX8
- SATB2
- immunohistochemistry
- mucinous
- napsin A
- ovarian cancer
PubMed: MeSH publication types
- Journal Article
Cite this
Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma. / Bassiouny, Dina; Ismiil, Nadia; Dubé, Valerie; Han, Guangming; Cesari, Matthew; Lu, Fang I.; Slodkowska, Elzbieta; Parra-Herran, Carlos; Chiu, Hak Fai; Naeim, Magda; Li, Nim; Khalifa, Mahmoud A; Nofech-Mozes, Sharon.
In: International Journal of Surgical Pathology, Vol. 26, No. 4, 01.06.2018, p. 306-317.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma
AU - Bassiouny, Dina
AU - Ismiil, Nadia
AU - Dubé, Valerie
AU - Han, Guangming
AU - Cesari, Matthew
AU - Lu, Fang I.
AU - Slodkowska, Elzbieta
AU - Parra-Herran, Carlos
AU - Chiu, Hak Fai
AU - Naeim, Magda
AU - Li, Nim
AU - Khalifa, Mahmoud A
AU - Nofech-Mozes, Sharon
PY - 2018/6/1
Y1 - 2018/6/1
N2 - The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3%), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7%), 35 (97.2%), and 0 (0%), respectively. MMR proteins and ARID1A were retained in 100%; PTEN was lost in 4 (11.1%). P53 was aberrant in 10 (27.8%); none overexpressed p16. HER2 was positive in 6/35 (17.1%). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/−, CDX2+/−, PAX8−, ER−, PgR−, and SATB2−. HER2 positivity suggests a possible target for therapy in advanced disease.
AB - The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3%), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7%), 35 (97.2%), and 0 (0%), respectively. MMR proteins and ARID1A were retained in 100%; PTEN was lost in 4 (11.1%). P53 was aberrant in 10 (27.8%); none overexpressed p16. HER2 was positive in 6/35 (17.1%). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/−, CDX2+/−, PAX8−, ER−, PgR−, and SATB2−. HER2 positivity suggests a possible target for therapy in advanced disease.
KW - HER2
KW - HNF1b
KW - PAX8
KW - SATB2
KW - immunohistochemistry
KW - mucinous
KW - napsin A
KW - ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=85041922271&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041922271&partnerID=8YFLogxK
U2 - 10.1177/1066896917752861
DO - 10.1177/1066896917752861
M3 - Article
C2 - 29338553
AN - SCOPUS:85041922271
VL - 26
SP - 306
EP - 317
JO - International Journal of Surgical Pathology
JF - International Journal of Surgical Pathology
SN - 1066-8969
IS - 4
ER -